Agency Information Collection Activities: Proposed Collection; Comment Request, 8802-8803 [E9-4088]
Download as PDF
<![CDATA[
8802
Federal Register / Vol. 74, No. 37 / Thursday, February 26, 2009 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting).
Contact Person: Bonnie L. Burgess-Beusse,
PhD, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, 301–435–
1783, beusseb@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Diversity
Fellowships: Division of Translational and
Clinical Sciences.
Date: March 24–25, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health. 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting).
Contact Person: John Firrell, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5213,
MSC 7854, Bethesda, MD 20892, 301–435–
2598, firrellj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Technologies in Cell Biology.
Date: March 24–25, 2009.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting).
Contact Person: Noni Byrnes, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5130,
MSC 7840, Bethesda, MD 20892, (301) 435–
1023, byrnesn@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 18, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–3944 Filed 2–25–09; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
VerDate Nov<24>2008
16:56 Feb 25, 2009
Jkt 217001
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Rapid HIV Testing
Clinical Information Form for the
Minority AIDS Initiative (MAI) for
Ethnic and Racial Minorities at Risk for
Substance Use and HIV/AID—In Use
Without OMB Approval
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA) Center for Substance Abuse
Treatment (CSAT), is requesting an
OMB review and approval of the
Minority AIDS Initiative (MAI) Rapid
HIV Testing Clinical Information Form
that will be utilized for ethnic and racial
minority groups at risk for substance use
and HIV/AIDS that are served by
CSAT’s TCE–HIV grantees. The MAI
HIV Rapid Testing Clinical Information
Form would allow SAMHSA/CSAT to
collect essential clinical information
that will be used for quality assurance,
quality performance, and product
monitoring on approximately 30,000
rapid HIV test kits to be provided to
ethnic and racial minority communities
at no cost to the recipient provider
organizations. The MAI Rapid HIV
Testing Clinical Information Form
would support quality of care, provide
adequate clinical and product
monitoring, and provide appropriate
safeguards against fraud, waste and
abuse of Federal funds. SAMHSA’s
approach would avoid unnecessary
delay in informing any person
potentially adversely affected by a test
kit recall or public health advisory. This
program is authorized under Section
509 of the Public Health Service (PHS)
Act [42 U.S.C. 290bb–2].
The goals of SAMHSA’s MAI
initiative are to: (1) Increase the access
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
by racial and ethnic minority
communities to HIV testing, prevention,
care, and treatment services; (2)
implement strategies and activities
specifically targeted to the highest risk
and hardest-to-serve populations; (3)
reduce the stigma associated with HIV/
AIDS screening through outreach and
education, and (4) establish
collaborations or opportunities for
programs and/or activities to be
integrated.
The target populations for the
initiative are African Americans,
Hispanic/Latinos, and other racial and
ethnic minorities that are
disproportionately impacted by the twin
epidemics of HIV/AIDS and substance
abuse. Since 1981 approximately 1.7
million people are estimated to have
been infected with HIV in the U.S., and
more than 1.1 million are estimated to
be living with HIV/AIDS today. Racial
and ethnic minorities have been
disproportionately affected by HIV/
AIDS, and represent the majority of new
AIDS cases (70%), new HIV infections
(54%), prevalent HIV/AIDS cases (65%),
and AIDS deaths (72%) (CDC, 2006).
African Americans have been especially
affected by HIV/AIDS. More than half of
all new HIV infections and half of new
AIDS diagnoses occur in African
Americans despite their accounting for
approximately 12% of the U.S.
population. A similar impact exists
among Latinos, who represent 14% of
the U.S. population but account for 20%
of estimated AIDS diagnoses. Together,
Asian/Pacific Islanders and American
Indian/Alaska Natives represent 1%–
2% of new AIDS diagnoses.
The spread of HIV disease in the
United States has been partly fueled by
the use of illicit drugs. Injection drug
use (IDU) is directly related to HIV
transmission through the sharing of
drug equipment. According to CDC’s
latest report on 2006 rates, IDUs
accounted for 12 percent of estimated
new HIV infections. CDC’s historical
trend analysis indicates that new
infections have declined dramatically in
this population over time and confirm
the substantial evidence to date of
success in reducing HIV infections
among IDUs. Despite these declines,
rates of HIV and AIDS continue to rise
among certain groups including men
who have sex with men, high risk
heterosexual women and ethnic and
racial minority groups due to non-IDU
drugs and alcohol that interfere with
judgment about sexual and other types
of behaviors.
The estimated hour burden is
presented in the following table:
E:\FR\FM\26FEN1.SGM
26FEN1
8803
Federal Register / Vol. 74, No. 37 / Thursday, February 26, 2009 / Notices
Responses/
respondent
Number of respondents
30,000 ..........................................................................................................................................
Send comments to Summer King,
SAMHSA Reports Clearance Officer,
Room 7–1044, One Choke Cherry Road,
Rockville, MD 20857 and e-mail her a
copy at summer.king@samhsa.hhs.gov.
Written comments should be received
within 60 days of this notice.
Dated: February 20, 2009.
Elaine Parry,
Director, Office of Program Services.
[FR Doc. E9–4088 Filed 2–25–09; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Notification of Intent To Use
Schedule III, IV, or V Opioid Drugs for
the Maintenance and Detoxification
Treatment of Opiate Addiction Under
21 U.S.C. 823(g)(2) (OMB No. 0930–
0234)—Revision
The Drug Addiction Treatment Act of
2000 (‘‘DATA,’’ Pub. L. 106–310)
amended the Controlled Substances Act
(21 U.S.C. 823(g)(2)) to permit
practitioners (physicians) to seek and
obtain waivers to prescribe certain
approved narcotic treatment drugs for
the treatment of opiate addiction. The
legislation sets eligibility requirements
and certification requirements as well as
an interagency notification review
process for physicians who seek
waivers. The legislation was amended
in 2005 to eliminate the patient limit for
physicians in group practices, and in
2006, to permit certain physicians to
treat up to 100 patients.
To implement these provisions,
SAMHSA developed a notification form
(SMA–167) that facilitates the
submission and review of notifications.
The form provides the information
necessary to determine whether
practitioners (i.e., independent
physicians) meet the qualifications for
waivers set forth under the new law.
Use of this form will enable physicians
to know they have provided all
information needed to determine
whether practitioners are eligible for a
waiver.
However, there is no prohibition on
use of other means to provide requisite
information. The Secretary will convey
notification information and
determinations to the Drug Enforcement
Administration (DEA), which will
assign an identification number to
qualifying practitioners; this number
will be included in the practitioner’s
registration under 21 U.S.C. 823(f).
Practitioners may use the form for
three types of notification: (a) New, (b)
immediate, and (c) to notify of their
intent to treat up to 100 patients. Under
‘‘new’’ notifications, practitioners may
make their initial waiver requests to
SAMHSA. ‘‘Immediate’’ notifications
inform SAMHSA and the Attorney
General of a practitioner’s intent to
prescribe immediately to facilitate the
Number of
respondents
Purpose of submission
Burden hours
1
.167
Total burden
hours
5,010
treatment of an individual (one) patient
under 21 U.S.C. 823(g)(2)(E)(ii). Finally,
the form may be used by physicians
with waivers to certify their need and
intent to treat up to 100 patients.
The form collects data on the
following items: Practitioner name;
State medical license number and DEA
registration number; address of primary
location, telephone and fax numbers; email address; purpose of notification
new, immediate, or renewal;
certification of qualifying criteria for
treatment and management of opiate
dependent patients; certification of
capacity to refer patients for appropriate
counseling and other appropriate
ancillary services; certification of
maximum patient load, certification to
use only those drug products that meet
the criteria in the law. The form also
notifies practitioners of Privacy Act
considerations, and permits
practitioners to expressly consent to
disclose limited information to the
SAMHSA Buprenorphine Physician
Locator.
Since July 2002, SAMHSA has
received over 17,000 notifications and
has certified almost 16,000 physicians.
Eighty-one percent of the notifications
were submitted by mail or by facsimile,
with approximately twenty percent
submitted through the Web based online
system. Approximately 60 percent of the
certified physicians have consented to
disclosure on the SAMHSA
Buprenorphine Physician Locator.
Respondents may submit the form
electronically, through a dedicated Web
page that SAMHSA will establish for the
purpose, as well as via U.S. mail.
The following table summarizes the
estimated annual burden for the use of
this form.
Responses
per
respondent
Burden per
response
(hr.)
Total burden
(hrs)
Initial Application for Waiver ............................................................................
Notification to Prescribe Immediately ..............................................................
Notice to Treat up to 100 patients ...................................................................
1,500
50
500
1
1
1
.083
.083
.040
125
4
20
Total ...................................................................................................
2,050
........................
........................
149
Written comments and
recommendations concerning the
proposed information collection should
be sent by March 30, 2009 to: SAMHSA
Desk Officer, Human Resources and
VerDate Nov<24>2008
16:56 Feb 25, 2009
Jkt 217001
Housing Branch, Office of Management
and Budget, New Executive Office
Building, Room 10235, Washington, DC
20503; due to potential delays in OMB’s
receipt and processing of mail sent
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
through the U.S. Postal Service,
respondents are encouraged to submit
comments by fax to: 202–395–6974.
E:\FR\FM\26FEN1.SGM
26FEN1
]]>Agencies
[Federal Register Volume 74, Number 37 (Thursday, February 26, 2009)]
[Notices]
[Pages 8802-8803]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-4088]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection;
Comment Request
In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction
Act of 1995 concerning opportunity for public comment on proposed
collections of information, the Substance Abuse and Mental Health
Services Administration (SAMHSA) will publish periodic summaries of
proposed projects. To request more information on the proposed projects
or to obtain a copy of the information collection plans, call the
SAMHSA Reports Clearance Officer on (240) 276-1243.
Comments are invited on: (a) Whether the proposed collections of
information are necessary for the proper performance of the functions
of the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Proposed Project: Rapid HIV Testing Clinical Information Form for the
Minority AIDS Initiative (MAI) for Ethnic and Racial Minorities at Risk
for Substance Use and HIV/AID--In Use Without OMB Approval
The Substance Abuse and Mental Health Services Administration's
(SAMHSA) Center for Substance Abuse Treatment (CSAT), is requesting an
OMB review and approval of the Minority AIDS Initiative (MAI) Rapid HIV
Testing Clinical Information Form that will be utilized for ethnic and
racial minority groups at risk for substance use and HIV/AIDS that are
served by CSAT's TCE-HIV grantees. The MAI HIV Rapid Testing Clinical
Information Form would allow SAMHSA/CSAT to collect essential clinical
information that will be used for quality assurance, quality
performance, and product monitoring on approximately 30,000 rapid HIV
test kits to be provided to ethnic and racial minority communities at
no cost to the recipient provider organizations. The MAI Rapid HIV
Testing Clinical Information Form would support quality of care,
provide adequate clinical and product monitoring, and provide
appropriate safeguards against fraud, waste and abuse of Federal funds.
SAMHSA's approach would avoid unnecessary delay in informing any person
potentially adversely affected by a test kit recall or public health
advisory. This program is authorized under Section 509 of the Public
Health Service (PHS) Act [42 U.S.C. 290bb-2].
The goals of SAMHSA's MAI initiative are to: (1) Increase the
access by racial and ethnic minority communities to HIV testing,
prevention, care, and treatment services; (2) implement strategies and
activities specifically targeted to the highest risk and hardest-to-
serve populations; (3) reduce the stigma associated with HIV/AIDS
screening through outreach and education, and (4) establish
collaborations or opportunities for programs and/or activities to be
integrated.
The target populations for the initiative are African Americans,
Hispanic/Latinos, and other racial and ethnic minorities that are
disproportionately impacted by the twin epidemics of HIV/AIDS and
substance abuse. Since 1981 approximately 1.7 million people are
estimated to have been infected with HIV in the U.S., and more than 1.1
million are estimated to be living with HIV/AIDS today. Racial and
ethnic minorities have been disproportionately affected by HIV/AIDS,
and represent the majority of new AIDS cases (70%), new HIV infections
(54%), prevalent HIV/AIDS cases (65%), and AIDS deaths (72%) (CDC,
2006). African Americans have been especially affected by HIV/AIDS.
More than half of all new HIV infections and half of new AIDS diagnoses
occur in African Americans despite their accounting for approximately
12% of the U.S. population. A similar impact exists among Latinos, who
represent 14% of the U.S. population but account for 20% of estimated
AIDS diagnoses. Together, Asian/Pacific Islanders and American Indian/
Alaska Natives represent 1%-2% of new AIDS diagnoses.
The spread of HIV disease in the United States has been partly
fueled by the use of illicit drugs. Injection drug use (IDU) is
directly related to HIV transmission through the sharing of drug
equipment. According to CDC's latest report on 2006 rates, IDUs
accounted for 12 percent of estimated new HIV infections. CDC's
historical trend analysis indicates that new infections have declined
dramatically in this population over time and confirm the substantial
evidence to date of success in reducing HIV infections among IDUs.
Despite these declines, rates of HIV and AIDS continue to rise among
certain groups including men who have sex with men, high risk
heterosexual women and ethnic and racial minority groups due to non-IDU
drugs and alcohol that interfere with judgment about sexual and other
types of behaviors.
The estimated hour burden is presented in the following table:
[[Page 8803]]
----------------------------------------------------------------------------------------------------------------
Responses/ Total burden
Number of respondents respondent Burden hours hours
----------------------------------------------------------------------------------------------------------------
30,000.......................................................... 1 .167 5,010
----------------------------------------------------------------------------------------------------------------
Send comments to Summer King, SAMHSA Reports Clearance Officer,
Room 7-1044, One Choke Cherry Road, Rockville, MD 20857 and e-mail her
a copy at summer.king@samhsa.hhs.gov. Written comments should be
received within 60 days of this notice.
Dated: February 20, 2009.
Elaine Parry,
Director, Office of Program Services.
[FR Doc. E9-4088 Filed 2-25-09; 8:45 am]
BILLING CODE 4162-20-P
